Skip to main
AVBP

AVBP Stock Forecast & Price Target

AVBP Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 90%
Buy 10%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ArriVent BioPharma is well-positioned for long-term success with its pipeline of differentiated medicines and strong financial backing, but investors should also consider the potential challenges and risks in the competitive biopharmaceutical industry.

Bears say

ArriVent BioPharma is a clinical-stage biopharmaceutical company with a healthy balance sheet and a lead candidate, firmonertinib, in a pivotal Exon 20ins study. However, the company's reliance on this single molecule and its narrow focus on a specific mutation in NSCLC raises concerns about its long-term potential and the potential for competition. Additionally, the high variability of PACC mutations and potential limitations in blood-brain barrier penetration highlight uncertainties in the company's clinical candidate and raise doubts about its ability to address significant unmet needs in solid tumors.

AVBP has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 90% of analysts recommend a Strong Buy, 10% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ArriVent Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ArriVent Biopharma Inc (AVBP) Forecast

Analysts have given AVBP a Strong Buy based on their latest research and market trends.

According to 10 analysts, AVBP has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ArriVent Biopharma Inc (AVBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.